Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP). The treatment, AGTC-501, is a gene replacement therapy and was originally developed by the company AGTC and then acquired by Beacon in 2023.
This trial is a global, randomized trial and will involve approximately 75 participants to test the efficacy and safety of the gene replacement therapy. Results from the trial will be shared in the coming years.
About Fighting Blindness Canada
Fighting Blindness Canada (FBC) is the largest charitable funder of vision research in Canada.
Over our 49-year history, FBC has contributed critical funding for the development of sight-saving treatments and cures for blinding eye diseases. By raising and stewarding funds, FBC is helping drive forward research that supports our goal of understanding why vision loss occurs, how it can be slowed and how sight can be restored.
We are an invaluable resource for individuals and families impacted by blindness, providing accurate eye health information through our website and educational events, as well as engaging with government and other stakeholders to advance better vision health policies.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
